These usually diminish over time
According to analysts, the price agreement with the White House may squeeze revenues in the short term, but it significantly expands access to treatment, adding up to 40 million potential US patients eligible for anti-obesity therapy
Download our GLP-1 app to Turn Your Weight Loss Journey into Your Favorite Game Blood tests give periodic snapshots, and tracking day-to-day habits, symptoms, and consistency helps you see patterns labs alone miss
Reddy's, Alkem, Biocon and OneSource Specialty Pharma are seen as better positioned to capitalise, aided by existing diabetes portfolios and partnerships.Ancillary beneficiaries are also expected, including Shaily Engineering Plastics, a key global supplier of pen devices used in injectable therapies, which could see meaningful demand growth as generic launches scale up.